E
Emmanuel Nowak
Researcher at French Institute of Health and Medical Research
Publications - 120
Citations - 3907
Emmanuel Nowak is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Population & Randomized controlled trial. The author has an hindex of 29, co-authored 109 publications receiving 2446 citations. Previous affiliations of Emmanuel Nowak include University of Western Brittany & European University of Brittany.
Papers
More filters
Journal ArticleDOI
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Laurent Meijer,Deborah J. Nelson,Vladimir Riazanski,Aida G. Gabdoulkhakova,Geneviève Héry-Arnaud,Rozenn Le Berre,Nadège Loaëc,Nassima Oumata,Hervé Galons,Emmanuel Nowak,L. Guéganton,Guillaume Dorothée,Michaela Prochazkova,Bradford Hall,Ashok B. Kulkarni,Robert D. Gray,Adriano G. Rossi,Véronique Witko-Sarsat,Caroline Norez,Frédéric Becq,Denis Ravel,Dominique Mottier,Gilles Rault +22 more
TL;DR: The fact that (R)-roscovitine has undergone extensive preclinical safety/pharmacology studies, and phase I and II clinical trials in cancer patients, encourages its repurposing as a CF drug candidate.
Journal ArticleDOI
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Valérie Devauchelle-Pensec,Xavier Mariette,Sandrine Jousse-Joulin,Jean-Marie Berthelot,Aleth Perdriger,Xavier Puéchal,Véronique Le Guern,Jean Sibilia,Jacques-Eric Gottenberg,Laurent Chiche,Eric Hachulla,Pierre Yves Hatron,Vincent Goëb,Gilles Hayem,Jacques Morel,Charles Zarnitsky,Jean Jacques Dubost,Jacques-Olivier Pers,Emmanuel Nowak,Alain Saraux +19 more
TL;DR: This multicenter, double-blind, placebo-controlled, randomized trial found that rituximab alleviated some symptoms at week 6 but did not alleviate symptoms or improve global activity score at month 6 in adults with recent-onset or systemic pSS.
Journal ArticleDOI
Contribution of salivary gland ultrasonography to the diagnosis of Sjögren's syndrome: toward new diagnostic criteria?
Divi Cornec,Sandrine Jousse-Joulin,Jacques-Olivier Pers,Thierry Marhadour,Béatrice Cochener,Sylvie Boisramé-Gastrin,Emmanuel Nowak,Pierre Youinou,Alain Saraux,Valérie Devauchelle-Pensec +9 more
TL;DR: Modifications of the AECG criteria, including the addition of a SGUS score, notably improved diagnostic performance and suggested modifications of the American-European Consensus Group (AECG) classification criteria.
Journal ArticleDOI
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Alice Tison,Gilles Quere,Laurent Misery,Elisa Funck-Brentano,François-Xavier Danlos,Emilie Routier,Caroline Robert,Yohann Loriot,Olivier Lambotte,Bertille Bonniaud,Camille Scalbert,Sarah Maanaoui,Thierry Lesimple,Stéphanie Martinez,Marie Marcq,Christos Chouaid,Catherine Dubos,Florence Brunet-Possenti,C. Stavris,Laurent Chiche,Nathalie Beneton,Sandrine Mansard,Florian Guisier,Hélène Doubre,François Skowron,François Aubin,Ouidad Zehou,Christophe Roge,Mickaël Lambert,Anne Pham-Ledard,Marie Beylot-Barry,R. Veillon,Nora Kramkimel,Damien Giacchero,Julie De Quatrebarbes,Catherine Michel,Jean-Bernard Auliac,Gilles Gonzales,Chantal Decroisette,Gwenaelle Le Garff,Ioana Carpiuc,Hervé Vallerand,Emmanuel Nowak,Divi Cornec,Marie Kostine,Groupe de cancérologie cutanée,Club Rhumatismes et Inflammations +46 more
TL;DR: This study evaluated the safety and efficacy of ICIs in patients with preexisting autoimmune disease and cancer and found ICIs were safe and effective in both cancer and autoimmune diseases.
Journal ArticleDOI
Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria
Pierre-Yves Le Roux,Thomas Gastinne,Steven Le Gouill,Emmanuel Nowak,Caroline Bodet-Milin,Solène Querellou,Beatrice Mahe,Viviane Dubruille,Nicolas Blin,Pierre Salaun,Françoise Bodere-Kraeber +10 more
TL;DR: This study confirms the high NPV of interim PET/CT for predicting treatment outcome in HL and a probably better prognostic value using a higher threshold for positivity even after four cycles of chemotherapy as used in Gallamini and London criteria.